TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
  • Bausch Health Companies Inc. (TSX: BHC) Latest News

    Investing

    Valeant Pharmaceuticals Intl Inc. Crushed by Citron Research: Find Out Who’s Next

    Andrew Left of Citron Research has another top pick for short-sellers looking for another opportunity to capitalize on accounting manipulations…

    Read more »

    The Motley Fool
    Investing

    Will These Companies Be Back in Vogue in 2017?

    Will shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), BlackBerry Ltd. (TSX:BB)(NASDAQ:BBRY), or Bombardier, Inc. (TSX:BBD.B) be back in vogue in…

    Read more »

    Investing

    Checklist: How to Find a Great Stock

    Free cash flow, low debt levels, and strong shareholder returns are paramount to the success of an investment. CCL Industries…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Should You Take a Contrarian Shot?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is hitting new multi-year lows. Is the bottom in sight?

    Read more »

    The Motley Fool
    Investing

    Why I’m Avoiding Valeant Pharmaceutical Intl Inc. Like the Plague

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) could be many years away from seeing its stock rally.

    Read more »

    Investing

    Will Valeant Pharmaceuticals Intl Inc. Survive the Trump Presidency?

    With President Trump openly critical of price-hiking pharmaceutical companies, can Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) survive the next four years?

    Read more »

    The Motley Fool
    Investing

    How 2017 Will Unfold for Valeant Pharmaceuticals Intl Inc.

    A mountain of debt, difficult no-win decisions, and a potential battle with the Trump administration are just some of the…

    Read more »

    The Motley Fool
    Investing

    Explaining the Interest Costs of Valeant Pharmaceuticals Intl Inc.

    With crippling interest costs, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will implode by the end of 2017.

    Read more »

    The Motley Fool
    Investing

    Simple Math Doesn’t Work at Valeant Pharmaceuticals Intl Inc.

    Although Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) announced major news in the past week, this will not change the end result:…

    Read more »

    The Motley Fool
    Tech Stocks

    Valeant Pharmaceuticals Intl Inc. on Fire to Start the Year

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has made some huge sales in the new year, helping the company to offload some…

    Read more »

    The Motley Fool
    Investing

    On the Move! Valeant Pharmaceuticals Intl Inc. Rises Again

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) announced the sale of some non-core assets this week which will help pay down the…

    Read more »

    Investing

    Valeant Pharmaceuticals Intl Inc. Just Sold Over US$2 Billion in Assets: What Now?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is finally selling assets, but the proceeds don't cover enough of the mountain of debt…

    Read more »